Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04289727 · ClinicalTrials.gov registry record

Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength

A clinical trial, sponsored by Columbia University.

Completed
Registry status
86
Enrollment target

NCT04289727: Completed study, sponsored by Columbia University.

NCT04289727 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04289727 has completed, sponsored by Columbia University.

COMPLETED
Registry status
86 participants
Enrollment target

Study Summary

The purpose of this research study is to find out how bones are affected in children and adolescents with type 1 diabetes (T1D) as compared to children and adolescents without type 1 diabetes.

Primary Outcome

Measures of HRpQCT

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2020-01-01
Est. Completion 2025-09-08
Columbia University

958 total trials

What the finished NCT04289727 record still lists

NCT04289727 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT04289727 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04289727 about?

NCT04289727 is a clinical study titled "Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength". The purpose of this research study is to find out how bones are affected in children and adolescents with type 1 diabetes (T1D) as compared to children and adolescents without type 1 diabetes.

What is the current status of trial NCT04289727?

This trial is currently completed. The enrollment target is 86 participants. The study started on 2020-01-01. Estimated completion is 2025-09-08.

Who is sponsoring clinical trial NCT04289727?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04289727, the US trial registry maintained by the National Library of Medicine. NCT04289727 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.